Objective:

To develop a prognostic tool specifically for predicting outcomes in uHCC patients receiving TACE combined with sintilimab and bevacizumab therapy.

Approach:

Key Findings:

• AFP, ALP, and TBS were confirmed as independent OS predictors, with the AAT model outperforming individual factors.
• The AAT model achieved ROC curve areas of 0.813 and 0.819 in training and validation cohorts, indicating strong predictive capability.
• The AAT score stratified patients into low, median, and high-risk groups with distinct 2-year OS rates of 80.0%, 48.0%, and 4.0%, respectively.

Interpretation:

The AAT model effectively stratifies OS and PFS in uHCC patients undergoing TACE plus sintilimab and bevacizumab, providing a basis for personalized treatment decisions.

Limitations:

• Retrospective design may introduce selection bias, potentially affecting the reliability of the findings.
• Single-center data may limit generalizability to broader populations.

Conclusion:

The AAT model aids in guiding personalized treatment decisions for uHCC patients.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.